Page 98 - 2019_07 resto del Mondo-web

R.G. Morgan et al.
Acknowledgments
RGM is funded by a Kay Kendall Leukemia Fund (KKLF) Junior Fellowship (KKL1051), British Society for Haematology (BSH) Early Stage Research Start-up Grant (34725), and a Royal Society Research Grant (RG160682). JR is funded by Cancer Research Wales. AT and RLD received funding from a Bloodwise programme grant (13029). We are grateful to clini-
cal staff, including Lizzy Palmer and Julia Wolf, at the Bristol Royal Hospital for Children (BRHC) and the Bristol Haematology and Oncology Centre (BHOC) respectively, for collection of AML patient samples and supplying associated clinical data. We are also grateful to the patients and their families who gave permission for their cells to be used for research.
References
1. Nusse R, Clevers H. Wnt/beta-Catenin Signaling, Disease, and Emerging Therapeutic Modalities. Cell. 2017;169(6): 985-999.
2. LiVS,NgSS,BoersemaPJ,etal.Wntsignal- ing through inhibition of beta-catenin degra- dation in an intact Axin1 complex. Cell. 2012;149(6):1245-1256.
3. MorganRG,RidsdaleJ,TonksA,DarleyRL. Factors affecting the nuclear localization of beta-catenin in normal and malignant tissue. J Cell Biochem. 2014;115(8):1351-1361.
4. Simon M, Grandage VL, Linch DC, Khwaja A. Constitutive activation of the Wnt/beta- catenin signalling pathway in acute myeloid leukaemia. Oncogene. 2005;24(14):2410- 2420.
5. Ysebaert L, Chicanne G, Demur C, et al. Expression of beta-catenin by acute myeloid leukemia cells predicts enhanced clonogenic capacities and poor prognosis. Leukemia. 2006;20(7):1211-1216.
6. Wang Y, Krivtsov AV, Sinha AU, et al. The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science. 2010;327(5973):1650-1653.
7. ZhaoC,BlumJ,ChenA,etal.Lossofbeta- catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell. 2007; 12(6):528-541.
8. Muller-Tidow C, Steffen B, Cauvet T, et al. Translocation products in acute myeloid leukemia activate the Wnt signaling path- way in hematopoietic cells. Mol Cell Biol. 2004;24(7):2890-2904.
9. ColucciaAM,VaccaA,DunachM,etal.Bcr- Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phos- phorylation. EMBO J. 2007;26(5):1456-1466.
10. GriffithsEA,GoldingMC,SrivastavaP,etal. Pharmacological targeting of beta-catenin in normal karyotype acute myeloid leukemia blasts. Haematologica. 2015;100(2):e49-52.
11. Morgan RG, Pearn L, Liddiard K, et al. gamma-Catenin is overexpressed in acute myeloid leukemia and promotes the stabi- lization and nuclear localization of beta- catenin. Leukemia. 2013;27(2):336-343.
12. Luis TC, Ichii M, Brugman MH, Kincade P, Staal FJ. Wnt signaling strength regulates normal hematopoiesis and its deregulation is involved in leukemia development. Leukemia. 2012;26(3):414-421.
13. MorganRG,MortenssonE,LeggeDN,etal. LGR5 expression is regulated by EGF in early colorectal adenomas and governs EGFR inhibitor sensitivity. Br J Cancer. 2018;118(4):558-565.
14. Morey L, Brenner C, Fazi F, et al. MBD3, a component of the NuRD complex, facili- tates chromatin alteration and deposition of epigenetic marks. Mol Cell Biol. 2008; 28(19):5912-5923.
15. Boukarabila H, Saurin AJ, Batsche E, et al.
The PRC1 Polycomb group complex inter- acts with PLZF/RARA to mediate leukemic transformation. Genes Dev. 2009;23(10): 1195-1206.
16. Kim JJ, Khalid O, Vo S, Sun HH, Wong DT, Kim Y. A novel regulatory factor recruits the nucleosome remodeling complex to wing- less integrated (Wnt) signaling gene promot- ers in mouse embryonic stem cells. J Biol Chem. 2012;287(49):41103-41117.
17. Chiacchiera F, Rossi A, Jammula S, et al. Polycomb Complex PRC1 Preserves Intestinal Stem Cell Identity by Sustaining Wnt/beta-Catenin Transcriptional Activity. Cell Stem Cell. 2016;18(1):91-103.
18. Byers RJ, Currie T, Tholouli E, Rodig SJ, Kutok JL. MSI2 protein expression predicts unfavorable outcome in acute myeloid leukemia. Blood. 2011;118(10):2857-2867.
19. Kaeda J, Ringel F, Oberender C, et al. Up-reg- ulated MSI2 is associated with more aggres- sive chronic myeloid leukemia. Leuk Lymphoma. 2015;56(7):2105-2113.
20. LiZ,JinH,MaoG,WuL,GuoQ.Msi2plays a carcinogenic role in esophageal squamous cell carcinoma via regulation of the Wnt/beta- catenin and Hedgehog signaling pathways. Exp Cell Res. 2017;361(1):170-177.
21. Helsmoortel HH, De Moerloose B, Pieters T, et al. LIN28B is over-expressed in specific subtypes of pediatric leukemia and regulates lncRNA H19. Haematologica. 2016;101(6): e240-244.
22. Zhou J, Bi C, Ching YQ, et al. Inhibition of LIN28B impairs leukemia cell growth and metabolism in acute myeloid leukemia. J Hematol Oncol. 2017;10(1):138.
23. Tu HC, Schwitalla S, Qian Z, et al. LIN28 cooperates with WNT signaling to drive invasive intestinal and colorectal adenocarci- noma in mice and humans. Genes Dev. 2015;29(10):1074-1086.
24. Yassin ER, Abdul-Nabi AM, Takeda A, Yaseen NR. Effects of the NUP98-DDX10 oncogene on primary human CD34+ cells: role of a conserved helicase motif. Leukemia. 2010;24(5):1001-1011.
2009;114(10):2087-2096.
29. Naudin C, Hattabi A, Michelet F, et al.
PUMILIO/FOXP1 signaling drives expan- sion of hematopoietic stem/progenitor and leukemia cells. Blood. 2017;129(18):2493- 2506.
30. Lee KY, Chan KY, Tsang KS, et al. Ubiquitous expression of MAKORIN-2 in normal and malignant hematopoietic cells and its growth promoting activity. PLoS One. 2014;9(3):e92706.
31. Yang L, Han Y, Suarez Saiz F, Minden MD. A tumor suppressor and oncogene: the WT1 story. Leukemia. 2007;21(5):868-876.
32. Jamieson C, Sharma M, Henderson BR. Regulation of beta-catenin nuclear dynamics by GSK-3beta involves a LEF-1 positive feedback loop. Traffic. 2011;12(8):983-999.
33. Simcha I, Shtutman M, Salomon D, et al. Differential nuclear translocation and trans- activation potential of beta-catenin and plakoglobin. J Cell Biol. 1998;141(6):1433- 1448.
34. Krieghoff E, Behrens J, Mayr B. Nucleo-cyto- plasmic distribution of beta-catenin is regu- lated by retention. J Cell Sci. 2006;119(Pt 7):1453-1463.
35. Behrens J, von Kries JP, Kuhl M, et al. Functional interaction of beta-catenin with the transcription factor LEF-1. Nature. 1996; 382(6592):638-642.
36. Davies ML, Roberts GT, Stuart N, Wakeman JA. Analysis of a panel of antibodies to APC reveals consistent activity towards an unidentified protein. Br J Cancer. 2007; 97(3):384-390.
37. Daud SS. The Role of WNT Transcription Factor TCF7L2 in Acute Myeloid Leukaemia. Cardiff University. 2014. Available from: http:// orca.cf.ac.uk/id/eprint/57554 [Last accessed Jan 2019].
38. Petropoulos K, Arseni N, Schessl C, et al. A novel role for Lef-1, a central transcription mediator of Wnt signaling, in leukemogene- sis. J Exp Med. 2008;205(3):515-522.
39. Hovanes K, Li TW, Munguia JE, et al. Beta- catenin-sensitive isoforms of lymphoid enhancer factor-1 are selectively expressed in colon cancer. Nat Genet. 2001;28(1):53-
25. Gu TL, Mercher T, Tyner JW, et al. A novel
fusion of RBM6 to CSF1R in acute megakaryoblastic leukemia. Blood. 2007; 110(1):323-333. 57.
26. Ma Z, Morris SW, Valentine V, et al. Fusion of two novel genes, RBM15 and MKL1, in the t(1;22)(p13;q13) of acute megakaryoblas- tic leukemia. Nat Genet. 2001;28(3):220-221.
27. Wang Y XW, Wei SM, Chen XM, Wei L, Tian RH, Meng Li, Xiao BR, Wu PX, Yu YH. Highly expressed DDX10 promotes hepato- cellular carcinoma cell proliferation through Wnt/β-catenin signaling. Int J Clin Exp Pathol. 2017;10(5):6047-6053.
28. Niu C, Zhang J, Breslin P, Onciu M, Ma Z, Morris SW. c-Myc is a target of RNA-bind- ing motif protein 15 in the regulation of adult hematopoietic stem cell and megakaryocyte development. Blood.
40. Koch U, Wilson A, Cobas M, Kemler R, Macdonald HR, Radtke F. Simultaneous loss of beta- and gamma-catenin does not per- turb hematopoiesis or lymphopoiesis. Blood. 2008;111(1):160-164.
41. Trompouki E, Bowman TV, Lawton LN, et al. Lineage regulators direct BMP and Wnt pathways to cell-specific programs during differentiation and regeneration. Cell. 2011;147(3):577-589.
42. Prieve MG, Guttridge KL, Munguia JE, Waterman ML. The nuclear localization sig- nal of lymphoid enhancer factor-1 is recog- nized by two differentially expressed Srp1- nuclear localization sequence receptor pro-
1376
haematologica | 2019; 104(7)